A phase 2, randomized, double-blind, placebo-controlled, multicenter exploratory study to evaluate various pharmacodynamic effects of subcutaneously infused or injected pramlintide in obese subjects

Trial Profile

A phase 2, randomized, double-blind, placebo-controlled, multicenter exploratory study to evaluate various pharmacodynamic effects of subcutaneously infused or injected pramlintide in obese subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2015

At a glance

  • Drugs Pramlintide (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics
  • Sponsors Amylin Pharmaceuticals; AstraZeneca
  • Most Recent Events

    • 30 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top